Cystic Fibrosis Canada
New member
If you are a patient with the G551D mutation or a caregiver of a patient with the G551D mutation, your help is urgently needed in collecting patient letters and testimony on Kalydeco.
The Canadian Agency for Drugs and Technologies in Health (CADTH) is accepting patient input for the CF drug Kalydeco as part of the Common Drug Review (CDR). The CDR is a pan-Canadian process for conducting objective, rigorous reviews of the clinical, cost-effectiveness, and patient evidence for drugs. CDR also provides formulary listing recommendations to Canada’s publicly funded drug plans (except Quebec).
Cystic Fibrosis Canada will provide a submission to ensure that the CF patient voice is heard. Please help us achieve this by reaching out to patients currently on Kalydeco to provide testimonials or letters on their experiences using Kalydeco. We are extending this invitation to patients with the G551D mutation who are currently not using Kalydeco, to write on why access to KALYDECO is important to them. We would like receipt of letters and testimonials from patients no later than October 10th.
Please find the patient input template at the following link:
http://www.cysticfibrosis.ca/assets/files/pdf/2012-10-01 Kalydeco Patient Submission Form.pdf
This valuable patient evidence will strengthen the submission to the Common Drug Review and is vital to demonstrate the support for access to beneficial CF therapies like Kalydeco. If you would like further information, you can contact me here, or at asrisombun@cysticfibrosis.ca.
Thank you!
Anchalee
The Canadian Agency for Drugs and Technologies in Health (CADTH) is accepting patient input for the CF drug Kalydeco as part of the Common Drug Review (CDR). The CDR is a pan-Canadian process for conducting objective, rigorous reviews of the clinical, cost-effectiveness, and patient evidence for drugs. CDR also provides formulary listing recommendations to Canada’s publicly funded drug plans (except Quebec).
Cystic Fibrosis Canada will provide a submission to ensure that the CF patient voice is heard. Please help us achieve this by reaching out to patients currently on Kalydeco to provide testimonials or letters on their experiences using Kalydeco. We are extending this invitation to patients with the G551D mutation who are currently not using Kalydeco, to write on why access to KALYDECO is important to them. We would like receipt of letters and testimonials from patients no later than October 10th.
Please find the patient input template at the following link:
http://www.cysticfibrosis.ca/assets/files/pdf/2012-10-01 Kalydeco Patient Submission Form.pdf
This valuable patient evidence will strengthen the submission to the Common Drug Review and is vital to demonstrate the support for access to beneficial CF therapies like Kalydeco. If you would like further information, you can contact me here, or at asrisombun@cysticfibrosis.ca.
Thank you!
Anchalee